Found: 11
Select item for more details and to access through your institution.
Dietary cystine restriction increases the proliferative capacity of the small intestine of mice.
- Published in:
- PLoS ONE, 2024, v. 19, n. 1, p. 1, doi. 10.1371/journal.pone.0290493
- By:
- Publication type:
- Article
Issue Cover.
- Published in:
- Liver International, 2023, v. 43, n. 3, p. i, doi. 10.1111/liv.15543
- By:
- Publication type:
- Article
Rifaximin stimulates nitrogen detoxification by PXR‐independent mechanisms in human small intestinal organoids.
- Published in:
- Liver International, 2023, v. 43, n. 3, p. 649, doi. 10.1111/liv.15491
- By:
- Publication type:
- Article
PPARγ lipodystrophy mutants reveal intermolecular interactions required for enhancer activation.
- Published in:
- Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-34766-9
- By:
- Publication type:
- Article
Post-Translational Modifications of FXR; Implications for Cholestasis and Obesity-Related Disorders.
- Published in:
- Frontiers in Endocrinology, 2021, v. 12, p. 1, doi. 10.3389/fendo.2021.729828
- By:
- Publication type:
- Article
Farnesoid X receptor and bile acids regulate vitamin A storage.
- Published in:
- Scientific Reports, 2019, v. 9, n. 1, p. 1, doi. 10.1038/s41598-019-55988-w
- By:
- Publication type:
- Article
Identification of FDA-approved drugs targeting the Farnesoid X Receptor.
- Published in:
- Scientific Reports, 2019, v. 9, n. 1, p. 1, doi. 10.1038/s41598-019-38668-7
- By:
- Publication type:
- Article
Quantitative liver proteomics identifies FGF19 targets that couple metabolism and proliferation.
- Published in:
- PLoS ONE, 2017, v. 12, n. 2, p. 1, doi. 10.1371/journal.pone.0171185
- By:
- Publication type:
- Article
The glucocorticoid mometasone furoate is a novel FXR ligand that decreases inflammatory but not metabolic gene expression.
- Published in:
- Scientific Reports, 2015, p. 14086, doi. 10.1038/srep14086
- By:
- Publication type:
- Article
Pharmacological Activation of the Bile Acid Nuclear Farnesoid X Receptor Is Feasible in Patients with Quiescent Crohn's Colitis.
- Published in:
- PLoS ONE, 2012, v. 7, n. 11, p. 1, doi. 10.1371/journal.pone.0049706
- By:
- Publication type:
- Article
Farnesoid X Receptor (FXR) Activation and FXR Genetic Variation in Inflammatory Bowel Disease.
- Published in:
- PLoS ONE, 2011, v. 6, n. 8, p. 1, doi. 10.1371/journal.pone.0023745
- By:
- Publication type:
- Article